| Age category |
---|
25–64 years | 65–74 years | 75–84 years |
---|
OR [95Â % CI] | p Value | OR [95Â % CI] | p Value | OR [95Â % CI] | p Value |
---|
Model 1a | 0.19 [0.10–0.36] | <0.0001 | 0.28 [0.17–0.46] | <0.0001 | 0.43 [0.30–0.62] | <0.0001 |
Model 2b | 0.35 [0.15–0.84] | 0.02 | 0.45 [0.22–0.92] | 0.03 | 0.39 [0.24–0.63] | <0.0001 |
- a Model 1 adjusted for sex for the total sample (n = 3475)
- b Model 2 adjusted for sex, body mass index ≥30 kg/m2, type of AMI, renal dysfunction, prior stroke, prior MI, history of diabetes, hypertension, hyperlipidemia, angina pectoris and chronic obstructive pulmonary disease, any in-hospital complication (without cardiac arrest), pre-hospital time, left ventricular ejection fraction, peak serum creatine phosphokinase (CPK) level, and in-hospital medication: dual antiplatelet therapy, beta-blockers, statins, and angiotensin-converting-enzyme inhibitors or angiotensin receptor blockers. As 23 patients had no data on peak serum CPK level, the total sample size was 3452